Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Inovio Pharmaceuticals (INO) Stock Price
Headlines about Inovio Pharmaceuticals (NASDAQ:INO) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Inovio Pharmaceuticals earned a coverage optimism score of 0.04 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.3268297300695 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have effected Accern’s scoring:
- Brokerages Expect Inovio Pharmaceuticals Inc (INO) Will Announce Quarterly Sales of $2.13 Million (americanbankingnews.com)
- Inovio Pharmaceuticals Inc (INO) Receives Consensus Recommendation of “Buy” from Brokerages (americanbankingnews.com)
- Zacks: Brokerages Expect Inovio Pharmaceuticals Inc (INO) Will Post Earnings of -$0.35 Per Share (americanbankingnews.com)
- Global Pol Polyprotein Market 2018 – GeoVax Labs, Inc., Inovio Pharmaceuticals, Inc., Johnson & Johnson (newszak.com)
- 200 days simple moving average (SMA200) Indicator under Consideration Inovio Pharmaceuticals, Inc. (NASDAQ:INO … (stocksnewspoint.com)
Inovio Pharmaceuticals remained flat at $$4.32 during midday trading on Friday, Marketbeat Ratings reports. 371,226 shares of the company traded hands, compared to its average volume of 765,873. Inovio Pharmaceuticals has a 12-month low of $3.64 and a 12-month high of $7.00. The stock has a market cap of $392.96 million, a P/E ratio of -3.96 and a beta of 2.64.
A number of brokerages have recently commented on INO. BidaskClub raised shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, May 18th. HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, May 16th. ValuEngine raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, May 18th. Finally, Maxim Group set a $8.00 target price on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, April 11th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $11.25.
In related news, CFO Peter Kies sold 35,000 shares of Inovio Pharmaceuticals stock in a transaction on Tuesday, July 10th. The shares were sold at an average price of $4.44, for a total transaction of $155,400.00. Following the sale, the chief financial officer now owns 97,088 shares of the company’s stock, valued at approximately $431,070.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 9.40% of the company’s stock.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Recommended Story: What are Closed-End Mutual Funds?
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.